Companion diagnostic ( CDx) clinical trials

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.